Form PTO-1594 (Rev. 07/05)

OMB Collection 0651-0027 (exp. 6/30/20

U.S. DEPARTMENT OF COMMERCE United States Patent and Trademark Office

To the Director of the U. S. Patent and Trademark Office: Ple	ase record the attached documents or the new address(es) below
1. Name of conveying party(ies): Winstrol, LLC	2. Name and address of receiving party(ies)  Additional names, addresses, or citizenship attached?  Merrill Lynch Capital, a division of  Name: Merrill Lynch Business Financial Service
☐ Individual(s) ☐ Association ☐ General Partnership ☐ Limited Partnership ☐ Corporation- State: Illinois ☐ Other ☐ Citizenship (see guidelines)	Internal Address: 16th Floor Street Address: 222 N, LaSalle Street City: Chicago State: IL Country: U.S.A. Zip: 60601
Additional names of conveying parties attached? Yes 🗸 N	O Association Citizenship
3. Nature of conveyance )/Execution Date(s):  Execution Date(s) December 22, 2006  ☐ Assignment ☐ Merger  ☐ Security Agreement ☐ Change of Name ☐ Other	General Partnership Citizenship Limited Partnership Citizenship Corporation Citizenship Delaware Other Citizenship If assignee is not domiciled in the United States, a domestic representative designation is attached: Yes No (Designations must be a separate document from assignment)
4. Application number(s) or registration number(s) as A. Trademark Application No.(s)	d identification or description of the Trademark.  B. Trademark Registration No.(s)  725,841
A. Trademark Application No.(s)      C. Identification or Description of Trademark(s) (and Filing 5. Name & address of party to whom correspondence.)	B. Trademark Registration No.(s) 725,841  Additional sheet(s) attached? Yes V N g Date if Application or Registration Number is unknown):
A. Trademark Application No.(s)      C. Identification or Description of Trademark(s) (and Filing)	B. Trademark Registration No.(s) 725,841  Additional sheet(s) attached? Yes V N g Date if Application or Registration Number is unknown):
A. Trademark Application No.(s)  C. Identification or Description of Trademark(s) (and Filin  5. Name & address of party to whom correspondence concerning document should be mailed:	B. Trademark Registration No.(s) 725,841  Additional sheet(s) attached? Yes N  g Date if Application or Registration Number is unknown):  6. Total number of applications and
A. Trademark Application No.(s)  C. Identification or Description of Trademark(s) (and Filin  5. Name & address of party to whom correspondence concerning document should be mailed:  Name: Magdalini Rizakos  Internal Address: C/O Latham & Watkins  Sears Tower, Suite 5800	B. Trademark Registration No.(s) 725,841  Additional sheet(s) attached? Yes No Note of Application or Registration Number is unknown):  6. Total number of applications and registrations involved:  7. Total fee (37 CFR 2.6(b)(6) & 3.41) \$40.00  Authorized to be charged by credit card Authorized to be charged to deposit account Final Enclosed  8. Payment Information:
A. Trademark Application No.(s)  C. Identification or Description of Trademark(s) (and Filing 5. Name & address of party to whom correspondence concerning document should be mailed:  Name: Magdalini Rizakos  Internal Address: c/o Latham & Watkins  Sears Tower, Suite 5800  Street Address: 233 S. Wacker Drive  City: Chicago  State: II Zip: 60606	B. Trademark Registration No.(s) 725,841  Additional sheet(s) attached? Yes No. (s)  g Date if Application or Registration Number is unknown):  6. Total number of applications and registrations involved:  7. Total fee (37 CFR 2.6(b)(6) & 3.41) \$40.00  Authorized to be charged by credit card Authorized to be charged to deposit account Final Enclosed  8. Payment Information: a. Credit Card Last 4 Numbers
A. Trademark Application No.(s)  C. Identification or Description of Trademark(s) (and Filing 5. Name & address of party to whom correspondence concerning document should be mailed:  Name: Magdalini Rizakos  Internal Address: c/o Latham & Watkins  Sears Tower, Suite 5800  Street Address: 233.S. Wacker Drive  City: Chicago	B. Trademark Registration No.(s) 725,841  Additional sheet(s) attached? Yes No possible if Application or Registration Number is unknown):  6. Total number of applications and registrations involved:  7. Total fee (37 CFR 2.6(b)(6) & 3.41) \$40.00  Authorized to be charged by credit card Authorized to be charged to deposit account Penclosed  8. Payment Information: a. Credit Card Last 4 Numbers Expiration Date b. Deposit Account Number
A. Trademark Application No.(s)  C. Identification or Description of Trademark(s) (and Filing 5. Name & address of party to whom correspondence concerning document should be mailed:  Name: Magdalini Rizakos Internal Address: _c/o Latham & Watkins  Sears Tower, Suite 5800  Street Address: 233.S. Wacker Drive  City: _Chicago  State: Zip: _60606  Phone Number: 312-993-2698  Fax Number: 312-993-9767	B. Trademark Registration No.(s) 725,841  Additional sheet(s) attached? Yes No Note of Application or Registration Number is unknown):  6. Total number of applications and registrations involved:  7. Total fee (37 CFR 2.6(b)(6) & 3.41) \$40.00  Authorized to be charged by credit card Authorized to be charged to deposit account Final Enclosed  8. Payment Information:

Docume 124 144 (Metallic Control of the USPTO, P.O. Box 1450, Alexandria, VA 22018-4460)

# MASTER REAFFIRMATION AND AMENDMENT TO SECURITY DOCUMENTS

THIS MASTER REAFFIRMATION AND AMENDMENT TO SECURITY DOCUMENTS ("Master Reaffirmation") is made as of December 22, 2006, by and among OVATION PHARMACEUTICALS, INC., an Illinois corporation ("Borrower"), OVATION HOLDINGS, LLC, a Delaware limited liability company ("Holdings"), OVATION PHARMACEUTICALS SERVICES, LLC, a Delaware limited liability company ("Ovation Services"), WINSTROL, LLC, an Illinois limited liability company ("Winstrol" and, together with Borrower, Holdings and Ovation Services, the "Debtors" and each a "Debtor"), and MERRILL LYNCH CAPITAL, a division of Merrill Lynch Business Financial Services Inc., as Administrative Agent ("Merrill Lynch" and "Administrative Agent"). Unless otherwise defined herein, capitalized terms used herein shall have the meanings ascribed to them in the Credit Agreement (as hereinafter defined).

#### WITNESSETH:

WHEREAS, Borrower, the financial institutions from time to time parties thereto, each as a lender (the "Existing Lenders"), and Merrill Lynch, as administrative agent, are parties to that certain Credit Agreement dated as of August 10, 2005 (as amended or supplemented from time to time prior to the date hereof, the "Existing Credit Agreement");

WHEREAS, Borrower, the financial institutions from time to time parties thereto, each as a Lender (the "Lenders"), and Merrill Lynch, as Administrative Agent, are parties to that certain Amended and Restated Credit Agreement of even date herewith (as amended, restated, supplemented or otherwise modified or extended from time to time, the "Credit Agreement"), which amends and restates the Existing Credit Agreement;

WHEREAS, Debtors have previously executed and delivered to Administrative Agent, for the benefit of the Existing Lenders and Administrative Agent, various guaranty, security and related documents in connection with the Existing Credit Agreement; and

WHEREAS, it is a condition precedent to making the loans, advances and other financial accommodations of Administrative Agent and Lenders under the Credit Agreement that the Debtors enter into this Master Reaffirmation to acknowledge and agree that the Continuing Security Documents (as hereinafter defined) and the liens, security interests and guarantees granted and issued thereunder, secure and guarantee the Obligations under the Credit Agreement.

NOW, THEREFORE, in consideration of the premises set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each of the undersigned agrees as follows:

- 1. <u>Continuing Security Documents</u>. "Continuing Security Documents" as used herein shall mean, collectively:
  - a. the Security Agreement (together with all amendments, supplements and counterparts, if any, from time to time thereto, the "Borrower Security Agreement"),

CH\902516.5

dated as of August 10, 2005 among Borrower and Merrill Lynch, in its capacity as Administrative Agent for the Existing Lenders;

- b. the Security Agreement (together with all amendments, supplements and counterparts, if any, from time to time thereto, the "Guarantor Security Agreement"), dated as of August 10, 2005 among Holdings, Ovation Services, Winstrol, Borrower and Merrill Lynch, in its capacity as Administrative Agent for the Existing Lenders;
- c. the Patent Security Agreement (together with all amendments, supplements, and counterparts, if any, from time to time thereto, the "Patent Security Agreement"), dated as of August 10, 2005, between Borrower, as Grantor, and Merrill Lynch, in its capacity as Administrative Agent for the Existing Lenders;
- d. the Trademark Security Agreement (together with all amendments, supplements, and counterparts, if any, from time to time thereto, the "Borrower Trademark Security Agreement"), dated as of August 10, 2005, between Borrower, as Grantor, and Merrill Lynch, in its capacity as Administrative Agent for the Existing Lenders;
- e. the Trademark Security Agreement (together with all amendments, supplements, and counterparts, if any, from time to time thereto, the "Winstrol Trademark Security Agreement"), dated as of August 10, 2005, between Winstrol, as Grantor, and Merrill Lynch, in its capacity as Administrative Agent for the Existing Lenders;
- f. the Pledge Agreement (together with all amendments, supplements, and counterparts, if any, from time to time thereto, the "Borrower Pledge Agreement"), dated as of August 10, 2005, between Borrower, as Pledgor, and Merrill Lynch, in its capacity as Administrative Agent for the Existing Lenders;
- g. the Pledge Agreement (together with all amendments, supplements, and counterparts, if any, from time to time thereto, the "Guarantor Pledge Agreement"), dated as of August 10, 2005, between Holdings, as Pledgor, and Merrill Lynch, in its capacity as Administrative Agent for the Existing Lenders;
- h. the Guaranty (together with all amendments, supplements, and counterparts, if any, from time to time thereto, the "Guaranty"), dated as of August 10, 2005, between Holdings, Ovation Services, Winstrol and Merrill Lynch, in its capacity as Administrative Agent for the Existing Lenders;
- i. the Agreement re: Pledged Accounts (together with all amendments, supplements, and counterparts, if any, from time to time thereto, the "<u>Pledged Accounts Agreement</u>"), dated as of June 30, 2005, between Borrower, Merrill Lynch, in its capacity as Administrative Agent for the Existing Lenders, and LaSalle Bank National Association;
- j. the Equitable Mortgage of Shares (together with all amendments, supplements, and counterparts, if any, from time to time thereto, the "Equitable Mortgage"), dated as of August 10, 2005, between Borrower (as successor in interest to Ovation Pharmaceuticals, LLC) and Merrill Lynch as Administrative Agent for the Existing Lenders; and

902516.5

k. each other Security Document (as defined in the Existing Credit Agreement) to which any Debtor is a party.

# 2. Amendments to Continuing Security Documents.

- a. Cross references in the Continuing Security Documents to particular section references in the Existing Credit Agreement, as applicable, shall be deemed to be cross references to the corresponding sections, as applicable, of the Credit Agreement.
- b. Attached hereto is Schedule I, which contains the information required to be set forth on the schedules to the Borrower Security Agreement, which information is current as of the date hereof.
- c. Attached hereto is Schedule II, which contains the information required to be set forth on the schedules to the Guarantor Security Agreement, which information is current as of the date hereof.
- d. Attached hereto is Schedule III, which contains the information required to be set forth on the Schedule to the Patent Security Agreement, which information is current as of the date hereof.
- e. Attached hereto is Schedule IV, which contains the information required to be set forth on the Schedule to the Borrower Trademark Security Agreement, which information is current as of the date hereof.
- f. Attached hereto is Schedule V, which contains the information required to be set forth on the Schedule to the Winstrol Trademark Security Agreement, which information is current as of the date hereof.
- g. Attached hereto is Schedule VI, which contains the information required to be set forth on the Schedule to the Borrower Pledge Agreement, which information is current as of the date hereof.
- h. Attached hereto is Schedule VII, which contains the information required to be set forth on the Schedule to the Guarantor Pledge Agreement, which information is current as of the date hereof.
- Agreement each Debtor, as borrower, debtor, grantor, mortgagor, pledgor, guarantor, assignor, or in other similar capacities, as applicable, in which such Debtor grants liens or security interests in its properties or otherwise acts as an accommodation party or guarantor, as the case may be, in any case under any one or more Continuing Security Documents to which it is a party, ratifies and reaffirms all of its payment and performance obligations, contingent or otherwise, under each of such Continuing Security Documents to which it is a party as deemed amended pursuant to Section 2 of this Master Reaffirmation. To the extent Debtors granted liens on or security interests in any of its properties pursuant to any such Continuing Security Document as security for the Obligations under or with respect to the Existing Credit Agreement and the other Financing Documents (as defined in the Existing Credit Agreement), Debtors hereby ratify and reaffirm such grant of

CH\902516.5

security and confirm and agree that such liens and security interests hereafter secure all of the Obligations under the Credit Agreement and the other Financing Documents. In each case each reference in such Continuing Security Documents to the obligations secured thereby shall be construed to hereafter mean and refer to the Obligations under the Credit Agreement and the Continuing Security Documents. Each Debtor hereby consents to the terms and conditions of the Credit Agreement and reaffirms its guaranty of all of the Obligations under or with respect to the Credit Agreement and the other Financing Documents. Each Debtor acknowledges receipt of a copy of the Credit Agreement and acknowledges that each of the Continuing Security Documents to which such Debtor is a party remains in full force and effect, and as hereby modified, ratified and confirmed. The execution of this Master Reaffirmation shall not operate as a waiver of any right, power or remedy of the Administrative Agent or Lenders, nor constitute a waiver of any provision of any of the Continuing Security Documents nor constitute a novation of any of the Obligations under the Credit Agreement or Continuing Security Documents as amended pursuant to Section 2 of this Master Reaffirmation.

- 4. <u>Successors and Assigns</u>. This Master Reaffirmation shall be binding upon the Debtors and upon their respective successors and assigns and shall inure to the benefit of Administrative Agent and the Lenders and their respective successors and assigns. The successors and assigns of such entities shall include, without limitation, their respective receivers, trustees, or debtors-in-possession.
- 5. <u>Further Assurances</u>. Each Debtor hereby agrees from time to time, as and when requested by Administrative Agent to execute and deliver or cause to be executed and delivered, all such documents, instruments and agreements and to take or cause to be taken such further or other action as Administrative Agent may reasonably deem necessary or desirable in order to carry out the intent and purposes of this Master Reaffirmation and any Security Documents to which such Debtor is a party.
- 6. <u>Definitions</u>. All references to the singular shall be deemed to include the plural and vice versa where the context so requires.
- 7. Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF ILLINOIS, WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES.
- Reaffirmation shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Master Reaffirmation shall be prohibited by or invalid under such law, such provision shall be ineffective to the extent of such prohibition or invalidity without invalidating the remainder of such provision or the remaining provisions of this Master Reaffirmation.
- 9. Merger. This Master Reaffirmation represents the final agreement of the parties hereto with respect to the matters contained herein and may not be contradicted by evidence of prior or contemporaneous agreements, or prior or subsequent oral agreements, among any of the Borrower, Administrative Agent or the Lenders.

CH\902516.5

- 10. <u>Execution in Counterparts</u>. This Master Reaffirmation may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.
- 11. <u>Section Headings</u>. The section headings herein are for convenience of reference only, and shall not affect in any way the interpretation of any of the provisions hereof.

Balance of Page Intentionally Left Blank
- Signature Page Follows -

CH\902516.5

WITNESS the due execution of this Master Reaffirmation by the respective duly authorized officers of the undersigned as of the date first written above.

#### **DEBTORS**

OVATION PHARMACEUTICALS, INC., as
Debtor

By
Title

Jeffrey S. Aronin
President & CEO

OVATION HOLDINGS, LLC, as Debtor

Title

Jeffrey S. Aronin
President & COO

OVATION PHARMACEUTICALS SERVICES, LLC, as Debtor

By
Title

Jeffrey S. Aronin
President & CEO

WINSTROL, LLC, as Debtor

By
Title Jeffrey S. Aronin
President & CEO

[Signature Page to Master Reaffirmation and Amendment to Collateral Documents]

## **ADMINISTRATIVE AGENT**

MERRILL LYNCH CAPITAL, a division of Merrill Lynch Business Financial Services Inc., as Administrative Agent

By: \_\_\_\_ Name: \_\_\_\_

Faraaz/Kamran

Title:

Vice President

[Signature Page to Master Reaffirmation and Amendment to Collateral Documents]

## SCHEDULE I

to

# MASTER REAFFIRMATION AND AMENDMENT TO SECURITY DOCUMENTS

# **BORROWER SECURITY AGREEMENT SCHEDULES**

#### Schedule 3.3

# **Collateral Locations, Chief Executive Office**

#### Chief Executive Office:

4 Parkway North, Suites 100, 200 and 300 Deerfield, Illinois 60015

#### Collateral Locations:

100 Corporate Drive, Suites 104 and 105 Lebanon, New Jersey 08833

4 Parkway North, Suite 200 Deerfield, Illinois 60015

## Collateral Locations (Inventory):

15 Ingram Blvd, Suite 100 LaVergne, TN 37086

3001 Red Lion Road Philadelphia, PA 19114

8900 Capital Blvd Raleigh, NC 27616

CH\902516.4

# **Federal Registration Collateral**

## U.S. Patents

20030082249 6,090,979 5,208,345 5,380,936 5,473,099 5,512,698 5,440,065 5,316,944 5,292,943 5,464,869 D300,879

# U.S. Trademarks

<u>Description</u>	Registration No.	Date Registered	
Cosmegen	759,115	10/29/63	
Elspar	920,555	09/21/71	
Mustargen	566,271	11/04/52	
Panhematin	1,317,567	02/05/85	
Peganone	627,656	05/29/56	
Desoxyn	1,521,495	01/24/89	
Desoxyn Gradumet	687,128	10/27/59	
Mebaral	321,093	01/15/35	
Nembutal	285,003	07/14/31	
Sabril	1,366,276	10/22/85	
T and Design	1,583,299	02/20/90	
T-Tab	1,598,120	05/29/90	
Ovation Logo	3,022,457	12/06/05	
Ovation Pharmaceuticals	3,022,458	12/06/05	
Chemet	1,443,827	06/23/87	

# **Trademark Applications**

<u>Description</u>	Application No.	Date Applied
Sabril	78/592,387	03/22/05
Sabrovil	78/779,408	12/22/05
Ovation Logo	78/725,983	10/04/05
Zabriga	78/779,481	12/22/05

CH\902516.4

# Chattel Paper, Letter-of-Credit Rights, Commercial Tort Claims, Documents, Titled Equipment

None

CH\902516.4

# **Deposit and Securities Accounts**

LaSalle Bank National Association Accounts

5800360835 5800360827

CH\902516.4

#### SCHEDULE II

to

# MASTER REAFFIRMATION AND AMENDMENT TO SECURITY DOCUMENTS

#### **GUARANTOR SECURITY AGREEMENT SCHEDULES**

#### Schedule 3.3

#### **Collateral Locations, Chief Executive Office**

#### Chief Executive Office:

4 Parkway North, Suite 200 Deerfield, Illinois 60015

#### Collateral Locations:

100 Corporate Drive, Suites 104 and 105 Lebanon, New Jersey 08833

4 Parkway North, Suite 200 Deerfield, Illinois 60015

#### Collateral Locations (Inventory):

15 Ingram Blvd, Suite 100 LaVergne, TN 37086

3001 Red Lion Road Philadelphia, PA 19114

8900 Capital Blvd Raleigh, NC 27616

CH\902516.4

# Federal Registration Collateral

U.S. Trademarks:

<u>Trademark</u> <u>Registration No.</u> <u>Registration Date</u>

Winstrol 725,841 1/02/62

CH\902516.4

# Chattel Paper, Letter-of-Credit Rights, Commercial Tort Claims, Documents, Titled Equipment

None

516.4

# **Deposit and Securities Accounts**

# LaSalle Bank National Association Accounts:

Holdings 5800360900

Ovation Services 5800430224, 5800430968

Winstrol 5800430638

CH\902516.4

**TRADEMARK** 

**REEL: 003451 FRAME: 0859** 

## **SCHEDULE III**

to

# MASTER REAFFIRMATION AND AMENDMENT TO SECURITY DOCUMENTS

## PATENT SECURITY AGREEMENT SCHEDULE

# **SCHEDULE 1**

#### **PATENTS**

Compositions containing capsaicin and its derivatives, and their use in treating mucositis  Process for the production of vinyl-GABA 6,090,979  Process for the productino of (S)-vinyl and allenyl 5,208,345 gaba  Process for preparing 4-amino-5-hexenoic acid 5,380,936  Ethyl 4-trichloroacetamido-4-hexenoate 5,473,099  Ethyl 6-formyloxy-4-hexenoate 5,512,698  Process for preparing 4-amino-5-hexenoic acid 5,440,065  Enzymatic resolution of a racemic mixture of gamma-amino acids using penicillin acylase  Method for the preparation of low odor 2, 3-dimercaptosuccinic acid  Use of dimercaptan acids, salts and metabolites thereof as antiretroviral treatments  Pharmaceutical tablet or similar article (Design)  D300,879	Patent Description	U.S. Patent No.
Process for the productino of (S)-vinyl and allenyl gaba  Process for preparing 4-amino-5-hexenoic acid 5,380,936  Ethyl 4-trichloroacetamido-4-hexenoate 5,473,099  Ethyl 6-formyloxy-4-hexenoate 5,512,698  Process for preparing 4-amino-5-hexenoic acid 5,440,065  Enzymatic resolution of a racemic mixture of gamma-amino acids using penicillin acylase  Method for the preparation of low odor 2, 3-dimercaptosuccinic acid  Use of dimercaptan acids, salts and metabolites thereof as antiretroviral treatments	•	20030082249
Process for preparing 4-amino-5-hexenoic acid  Ethyl 4-trichloroacetamido-4-hexenoate  5,473,099  Ethyl 6-formyloxy-4-hexenoate  5,512,698  Process for preparing 4-amino-5-hexenoic acid  5,440,065  Enzymatic resolution of a racemic mixture of gamma-amino acids using penicillin acylase  Method for the preparation of low odor 2, 3-dimercaptosuccinic acid  Use of dimercaptan acids, salts and metabolites thereof as antiretroviral treatments	Process for the production of vinyl-GABA	6,090,979
Ethyl 4-trichloroacetamido-4-hexenoate 5,473,099  Ethyl 6-formyloxy-4-hexenoate 5,512,698  Process for preparing 4-amino-5-hexenoic acid 5,440,065  Enzymatic resolution of a racemic mixture of gamma-amino acids using penicillin acylase  Method for the preparation of low odor 2, 3-dimercaptosuccinic acid  Use of dimercaptan acids, salts and metabolites thereof as antiretroviral treatments	· · · · · · · · · · · · · · · · · · ·	5,208,345
Ethyl 6-formyloxy-4-hexenoate 5,512,698  Process for preparing 4-amino-5-hexenoic acid 5,440,065  Enzymatic resolution of a racemic mixture of gamma-amino acids using penicillin acylase  Method for the preparation of low odor 2, 3-dimercaptosuccinic acid 5,292,943  Use of dimercaptan acids, salts and metabolites thereof as antiretroviral treatments	Process for preparing 4-amino-5-hexenoic acid	5,380,936
Process for preparing 4-amino-5-hexenoic acid  Enzymatic resolution of a racemic mixture of gamma- amino acids using penicillin acylase  Method for the preparation of low odor 2, 3- dimercaptosuccinic acid  Use of dimercaptan acids, salts and metabolites thereof as antiretroviral treatments  5,440,065  5,316,944  5,292,943  5,292,943	Ethyl 4-trichloroacetamido-4-hexenoate	5,473,099
Enzymatic resolution of a racemic mixture of gamma- amino acids using penicillin acylase  Method for the preparation of low odor 2, 3- dimercaptosuccinic acid  Use of dimercaptan acids, salts and metabolites thereof as antiretroviral treatments  5,316,944  5,292,943	Ethyl 6-formyloxy-4-hexenoate	5,512,698
amino acids using penicillin acylase  Method for the preparation of low odor 2, 3- dimercaptosuccinic acid  Use of dimercaptan acids, salts and metabolites thereof as antiretroviral treatments  5,292,943  5,292,943	Process for preparing 4-amino-5-hexenoic acid	5,440,065
dimercaptosuccinic acid  Use of dimercaptan acids, salts and metabolites thereof as antiretroviral treatments  5,464,869	·	5,316,944
as antiretroviral treatments		5,292,943
Pharmaceutical tablet or similar article (Design) D300,879	<b>A</b>	5,464,869
	Pharmaceutical tablet or similar article (Design)	D300,879

#### PATENT APPLICATIONS

Patent Application Description U.S. Patent Application No. Date Applied

**NONE** 

CH\902516.4

## **SCHEDULE IV**

to

# MASTER REAFFIRMATION AND AMENDMENT TO SECURITY DOCUMENTS

### BORROWER TRADEMARK SECURITY AGREEMENT SCHEDULE

## **SCHEDULE A**

## TRADEMARK REGISTRATIONS

Description	Registration No.	Date Registered
Cosmegen	759,115	10/29/63
Elspar	920,555	09/21/71
Mustargen	566,271	11/04/52
Panhematin	1,317,567	02/05/85
Peganone	627,656	05/29/56
Desoxyn	1,521,495	01/24/89
Desoxyn Gradumet	687,128	10/27/59
Mebaral	321,093	01/15/35
Nembutal	285,003	07/14/31
Sabril	1,366,276	10/22/85
T and Design	1,583,299	02/20/90
T-Tab	1,598,120	05/29/90
Ovation Logo	3,022,457	12/06/05
Ovation Pharmaceuticals	3,022,458	12/06/05
Chemet	1,443,827	06/23/87

# TRADEMARK APPLICATIONS

Trademark Application Description	U.S. Application No.	Date Applied
Sabril	78/592,387	03/22/05
Sabrovil	78/779,408	12/22/05
Ovation Logo	78/725,983	10/04/05
Zabriga	78/779,481	12/22/05

CH\902516.4

## SCHEDULE V

to

# MASTER REAFFIRMATION AND AMENDMENT TO SECURITY DOCUMENTS

#### WINSTROL TRADEMARK SECURITY AGREEMENT SCHEDULE

# **SCHEDULE A**

# TRADEMARK REGISTRATIONS

Trademark Description	U.S. Registration No.	Date Registered	
WINSTROL	725,841	01/02/62	

CH\902516.4

# **SCHEDULE VI**

to

# MASTER REAFFIRMATION AND AMENDMENT TO SECURITY DOCUMENTS

# BORROWER PLEDGE AGREEMENT SCHEDULE

# Exhibit A

# **Identification of Pledged Securities**

Issuer	Class or Other Description of Pledged Securities	Certificate Number (if applicable)	Number of Pledged Securities	Total Outstanding Securities	Percentage of Total Outstanding Securities Pledged
Ovation Pharmaceuticals Services, LLC	N/A	N/A	N/A	N/A	100%
Winstrol, LLC	N/A	N/A	N/A	N/A	100%

CH\902516.4

# **SCHEDULE VII**

to

# MASTER REAFFIRMATION AND AMENDMENT TO SECURITY DOCUMENTS

## **GUARANTOR PLEDGE AGREEMENT SCHEDULE**

# [To be confirmed by Borrower]

## Exhibit A

## **Identification of Pledged Securities**

# **Ovation Holdings, LLC:**

Issuer	Class or Other Description of Pledged Securities	Certificate Numbers (if applicable)	Number of Pledged Securities	Total Outstanding Securities	Percentage of Total Outstanding Securities Pledged
Ovation Pharmaceuticals, Inc. (an Illinois corporation)	Common Shares	8, 9 and 10	109,910,820.27	[110,070,820.2 7] To be updated by Ovation	[99.85%]  To be updated by Ovation

CH\902516.5

**RECORDED: 12/28/2006**